Long term safety of etanercept in elderly subjects with rheumatic diseases

Annals of the Rheumatic Diseases

Volumn 65, Issue 3, 2006, Pages 379-384

  Fleischmann, R ^a   Baumgartner, S W ^b   Weisman, M H ^c   Liu, T ^d   White, B ^d   Peloso, P ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Spokane Dermatology Clinic   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CHILD; DEATH; DEMYELINATING DISEASE; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INFANT; INFECTION; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DEMYELINATING DISEASES; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33144490233     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.035287     Document Type: Article

References (51)

1. Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999;42:415-20.
2. Rochon PA, Fortin PR, Dear KB, Minaker KL, Chalmers TC. Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med 1993;153:243-8.
3. Papadopoulos IA, Katsimbri P, Alamanos Y, Voulgari PV, Drosos AA. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003;23:70-4.
4. Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-Miller A, Hunder GG, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004;50:43-54.
5. Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, et al. Which subjects stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the early RA study (ERAS). Ann Rheum Dis 2002;61:335-40.
6. Olivieri I, van Tubergen A, Salvarani C, van der Linden S. Seronegative spondyloarthritides. Best Pract Res Clin Rheumatol 2002;16:723-39.
7. Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 1999;58:226-9.
8. Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset subjects. Ann Rheum Dis 1997;56:176-9.
9. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:212-17.
10. Aringer M. T lymphocyte activation - an inside overview. Acta Med Austriaca 2002;29:7-13.
11. Bingham CO III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl 2002;65:3-9.
12. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003;2:346-57.
13. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004;22:39-53.
14. Enbrel® (etanercept). Prescribing information. Amgen Inc, 2004.
15. Weinblatt ME, Genovese MC, Moreland LW, Bathon JM, Kremer JM, Fleischmann RM, et al. Efficacy and safety of over 7 years of etanercept (Enbrel®) therapy in North American patients with early and long-standing rheumatoid arthritis [abstract]. Arthritis Rheum 2004;50(suppl):S184.
16. Moreland LW, Margolies G, Heck LW Jr, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
17. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver Al, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
18. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
19. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
20. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
21. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
22. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
23. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pnarmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003;73:348-65.
24. Weinblatt M, Moreland LW, Schiff MH, Baumgartner SW, Tindall E, Fleischmann RM, et al. Long-term and phase III treatment of DMARD failing rheumatoid arthritis subjects with TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel™) [abstract]. Arthritis Rheum 1997;40(suppl):S126.
25. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Longterm safety and efficacy of etanercept in subjects with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
26. Dore R, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The safety and efficacy profile of etanercept (Enbrel®) liquid administered once weekly in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2004;50(suppl):S564-5.
27. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
28. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
29. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
30. Davis J Jr, Webb A, Lund S, Sack K. Results from an open-label extension study of etanercept in ankylosing spondylitis. Arthritis Rheum 2004;51:302-4.
31. Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004;3:391-403.
32. Humira (adalimumab). Product insert. Abbot Laboratories, 2004.
33. Remicade (infliximab). Prescribing information. Centocor Inc, 2004.
34. Ellerin R, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
35. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20.
36. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease in rheumatoid arthritis: a population-based cohort study [abstract]. Arthritis Rheum 2004;50(suppl):S688.
37. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475-9.
38. Jones SM, Harris CPD, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subtractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000;59:904-9.
39. Saricaoglu H, Güllülü S, Bülbül Baskin E, Cordan J, Tunali S. Echocardiographic findings in subjects with psoriatic arthropathy. J Eur Acad Dermatol Venereal 2003;17:414-17.
40. Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
41. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor α therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004;50:1040-50.
42. Kazi S, Cole J, Bisti A. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists [abstract]. Arthritis Rheum 2004;50(suppl):S374.
43. Mangano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004;22(suppl 35):S134-40.
44. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
45. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
46. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
47. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(suppl):1-12.
48. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002;62:2447-57.
49. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20(suppl 28):S16-22.
50. Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk therapies. Clin Exp Rheumatol 2004;22(suppl 35):S2-11.
51. Kochanek KD, Smith BL, Anderson RN. Deaths: preliminary data for 1999. Nat Vital Stat Rep 2001;49:1-48.